CTRI/2022/08/044617尚未招募未知
Induction chemotherapy (TP Regimen) followed by concurrent chemoradiation in loco-regionally advanced nasopharyngeal carcinoma - A feasibility study
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients will be eligible for inclusion in the study if they fulfilled all the following criteria:
- •Histologically confirmed, treatment-naÃ?¯ve, Locoregionally advanced nasopharyngeal carcinoma patients (Stage III & IVA-, as per AJCC 8th Edition),
- •Aged between >18 years- 60 years of age,
- •Good performance status (ECOG-0-2),
- •With adequate organ function at time of participation defined as: -
- •1.Hemoglobin ââ?°Â¥ 9 gm/dl; ANC ââ?°Â¥ 1500/mm3, Platelet Count ââ?°Â¥ 1,00,000/mm3
- •2.Liver Function Test: Bilirubin ââ?°Â¤ 2x upper limit of normal (ULN), AST/ALT/ALP ââ?°Â¤ 2.5 x ULN
- •3.Renal Function Test: Creatinine ââ?°Â¤ 1.5 ULN, Creatinine clearance ââ?°Â¥ 60ml/min.
- •Willing for treatment adherence, and willing for written informed consent
排除标准
- •Any of the following-
- •1.Patients with previous history of anti-cancer treatment, head and neck radiotherapy.
- •2.Patients with uncontrolled comorbidities or life-threatening diseases
- •3.Pregnant patient
- •4.Patients with distant metastases.
- •5.Patients with synchronous primary tumor
- •6.Evidence of moderate to severe hearing loss (as per Pure Tone Audiometry)
研究者
相似试验
进行中（未招募）
1 期
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01MedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008236Term: Cervical cancer stage IV Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008235Term: Cervical cancer stage III Class: 10029104Cervical CancerCTIS2024-513576-18-00Centre Hospitalier Universitaire De Toulouse310
暂停
3 期
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01Cervical Cancer2024-513576-18-00Centre Hospitalier Universitaire De Toulouse310
进行中（未招募）
不适用
Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.Inoperable squamous cell carcinoma of the head and neck.EUCTR2006-003381-33-SIInstitute of Oncology Ljubljana
进行中（未招募）
不适用
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumors of the oro- , hypopharynx and larynxTPF-C-HIT-Study - TPF-C-HITThe study is a phase II study of induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumors of the oro- , hypopharynx and laynx (TPF-C-HIT-Study)EUCTR2009-016489-10-DEniversity of Heidelberg
已完成
2 期
The phase II study of induction chemotherapy with cetuximab/S-1/low dose cisplatin for oral squamous cell carcinoma patientsoral squamous cell carcinomaJPRN-UMIN000014632The workshop of chemotherapy for oral cancer55